Results 11 to 20 of about 116,875 (269)
Cancer and hepatic steatosis [PDF]
ESMO Open, 2021 Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent and increasing liver disease, which encompasses a variety of liver diseases of different severity. NAFLD can lead to liver cirrhosis with all its complications as well as hepatocellular carcinoma (HCC). Steatosis of the liver is not only related to obesity and other metabolic risk factors,
Paternostro, R. +3 more
openaire +2 more sources
Steatosis and hepatitis C [PDF]
Gastroenterology Report, 2015 Hepatitis C virus (HCV) infection is a common liver disease worldwide with a high rate of chronicity (75-80%) in infected individuals. The chronic form of HCV leads to steatosis, cirrhosis and hepatocellualr carcinoma. Steatosis is prevalent in HCV patients (55%) due to a combination of viral factors (effect of viral proteins on some of the ...
Modaresi Esfeh, Jamak +1 more
openaire +2 more sources
Journal of Experimental Life Science, 2012 Minyak wijen (MW) yang banyak mengandung polyunsaturated fatty acid (PUFA) berfungsi menurunkan kadar lipid serum melalui induksi β oksidasi di mitokondria. Proses ini menghasilkan produk sampingan berupa radikal bebas. Vitamin E (α-tocopherol) diketahui
Authors Nur Khoma Fatmawati +2 more
doaj +1 more source
Gastroenterologìa, 2022 Background. Non-alcoholic fatty liver disease (NAFLD) ranks first among chronic liver diseases and covers almost a quarter of the population. Enough data have been accumulated on the mutual influence of metabolic changes and steatosis of the liver of ...
V.B. Yagmur +4 more
doaj +1 more source
Molecular Therapy: Nucleic Acids, 2022 Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration of ...
Stefano Bartesaghi +15 more
doaj +1 more source
Children, 2022 Background: Progressive Familial Intrahepatic cholestasis type I (PFIC1) is a rare congenital hepatopathy causing cholestasis with progressive liver disease.
Anna M. Kavallar +13 more
doaj +1 more source
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2020 Aim. To evaluate effects of ursodeoxycholic acid (UDCA) on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease (NAFLD).Materials and methods.
M. V. Mayevskaya +6 more
doaj +1 more source
НЕАЛКОГОЛЬНАЯ ЖИРОВАЯ БОЛЕЗНЬ ПЕЧЕНИ: ОТ ТЕОРИИ К ПРАКТИКЕ
Архивъ внутренней медицины, 2015 Non alcoholic hepar diseases (NAHD) is actual problem in the world medical servises. Despite to many new methods of diagnosis ant new pharmaceutical remedies, there are a lot of questions in many aspects of pathogenesis, diagnosis, treatment and ...
П. В. Селивёрстов
doaj +1 more source
HYPERAMMONIUM IN PATIENTS WITH PRECIRRHOSIS STAGE: CLINICAL REALITY?
Архивъ внутренней медицины, 2018 Ammonia belongs to the common neuro- and cytotoxic metabolites in the human. It is established that ammonia has hepatotoxic properties. Ammonia induces the formation of oxygen active forms, reduces the activity of endothelial NO synthase, dose ...
L. Yu. Ilchenko, I. G. Nikitin
doaj +1 more source
Insulin resistance and chronic hepatitis C [PDF]
Терапевтический архив, 2016 Aim. To estimate the spread of insulin resistance (IR) in patients with chronic hepatitis C (CHC) and to define the role of IR in the development of hepatic steatosis (HS) and in the progression of liver fibrosis (LF), as well as the impact of IR on the ...
L I Tkachenko, V V Maleev
doaj +1 more source